Статья

Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: Advantages of the heterologous DNA prime, protein boost immunization regimen

E. Alekseeva, I. Sominskaya, D. Skrastina, I. Egorova, E. Starodubova, E. Kushners, M. Mihailova, N. Petrakova, R. Bruvere, T. Kozlovskaya, M. Isaguliants, P. Pumpens,
2021

Background: Hepatitis C core protein is an attractive target for HCV vaccine aimed to exterminate HCV infected cells. However, although highly immunogenic in natural infection, core appears to have low immunogenicity in experimental settings. We aimed to design an HCV vaccine prototype based on core, and devise immunization regimens that would lead to potent anti-core immune responses which circumvent the immunogenicity limitations earlier observed. Methods: Plasmids encoding core with no translation initiation signal (pCMVcore); with Kozak sequence (pCMVcoreKozak); and with HCV IRES (pCMVcoreIRES) were designed and expressed in a variety of eukaryotic cells. Polyproteins corresponding to HCV 1b amino acids (aa) 1-98 and 1-173 were expressed in E. coli. C57BL/6 mice were immunized with four 25-μg doses of pCMVcoreKozak, or pCMV (I). BALB/c mice were immunized with 100 μg of either pCMVcore, or pCMVcoreKozak, or pCMVcoreIRES, or empty pCMV (II). Lastly, BALB/c mice were immunized with 20 μg of core aa 1-98 in prime and boost, or with 100 μg of pCMVcoreKozak in prime and 20 μg of core aa 1-98 in boost (III). Antibody response, [3H]-T-incorporation, and cytokine secretion by core/core peptide-stimulated splenocytes were assessed after each immunization. Results: Plasmids differed in core-expression capacity: mouse fibroblasts transfected with pCMVcore, pCMVcoreIRES and pCMVcoreKozak expressed 0.22 ± 0.18, 0.83 ± 0.5, and 13 ± 5 ng core per cell, respectively. Single immunization with highly expressing pCMVcoreKozak induced specific IFN-γ and IL-2, and weak antibody response. Single immunization with plasmids directing low levels of core expression induced similar levels of cytokines, strong T-cell proliferation (pCMVcoreIRES), and antibodies in titer 103(pCMVcore). Boosting with pCMVcoreKozak induced low antibody response, core-specific T-cell proliferation and IFN-γ secretion that subsided after the 3rd plasmid injection. The latter also led to a decrease in specific IL-2 secretion. The best was the heterologous pCMVcoreKozak prime/ protein boost regiment that generated mixed Th1/Th2-cellular response with core-specific antibodies in titer ≥ 3 × 103. Conclusion: Thus, administration of highly expressed HCV core gene, as one large dose or repeated injections of smaller doses, may suppress core-specific immune response. Instead, the latter is induced by a heterologous DNA prime/protein boost regiment that circumvents the negative effects of intracellular core expression. © 2009 Alekseeva et al; licensee BioMed Central Ltd.

Цитирование

Похожие публикации

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • E. Alekseeva
    Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga LV-1067, Latvia
  • I. Sominskaya
    Swedish Institute of Infectious Disease Control, SE-17182 Stockholm, Sweden
  • D. Skrastina
    Pasteur Institute, 197101 St Petersburg, Russian Federation
  • I. Egorova
    Microbiology and Tumorbiology Center, Karolinska Institutet, 17177 Stockholm, Sweden
  • E. Starodubova
    D.I. Ivanovsky Institute of Virology, 123098 Moscow, Russian Federation
  • E. Kushners
  • M. Mihailova
  • N. Petrakova
  • R. Bruvere
  • T. Kozlovskaya
  • M. Isaguliants
  • P. Pumpens
Название журнала
  • Genetic Vaccines and Therapy
Том
  • 7
Страницы
  • -
Ключевые слова
  • core protein; gamma interferon; hepatitis C vaccine; immunoglobulin G; interleukin 2; pCMVcoreKozak; primer DNA; retrovirus vector; unclassified drug; animal cell; animal experiment; antibody production; antibody response; article; cell proliferation; controlled study; cytokine release; DNA immunization; drug response; drug synthesis; Escherichia coli; eukaryotic cell; female; gene construct; gene expression; genetic transduction; hepatitis C; immune response; mouse; nonhuman; nucleotide sequence; retreatment; T lymphocyte; translation initiation; viral gene delivery system; viral gene therapy; Eukaryota; Hepatitis C virus; Mus
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus